

**Novartis India Limited** 

Inspire – BKC, 7<sup>th</sup> Floor, Bandra Kurla Complex Bandra East Mumbai 400 051 Tel: 0091 22 50243000

Web-site: <a href="www.novartis.in">www.novartis.in</a>
CIN – L24200MH1947PLC006104
Email: india.investors@novartis.com

## June 30, 2025

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

**Scrip code: 500672** 

Sub.: Intimation of the meeting of Board of Directors of Novartis India Limited ("the Company") and the Closure of Trading Window

Dear Sir/ Madam,

This is to inform that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company is scheduled to be held on **Tuesday**, **July 29, 2025**, to *inter alia*, consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2025.

In this connection, please note that pursuant to the 'Code of Conduct to regulate, monitor and report share trading by Designated Persons and their immediate relatives' ('Code') read with the applicable provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Trading Window for dealing in shares of the Company by Designated Persons / Insiders / Connected Persons and their immediate relatives will be closed with effect from Tuesday, July 01, 2025. The Trading Window will open 48 hours after the said financial results are declared to the Stock Exchange.

You are requested to take note of the above information.

Thanking You.

Yours Sincerely,

For Novartis India Limited

Maru Chandni Chandni Maru Digitally signed by Maru Chandni DN: dc=com, dc=novartis, ou=people, ou=LE, serialNumber=3190945, cn=Maru Chandni Date: 2025.06.30 12:37:22 +05'30'

Company Secretary and Compliance Officer

M No.: ACS 60291